Background: To analyze the outcome of abdominal aortic aneurysm (AAA) repair with elective open surgery (OS) versus endovascular aneurysm repair (EVAR) and assess the predictors of survival.
Methods: A retrospective cohort study was made of 1000 AAA treated between January 1998 and November 2014 (68.1% OS and 31.9% EVAR), with the comparison of comorbidity and complications, and survival analysis (Kaplan-Meier and Breslow). Multivariate logistic regression and Cox regression analyses were performed.
Results: The EVAR group had a higher prevalence of smokers (33.2% vs. 21%; P < 0.001), hypercholesterolemia (56.4% vs. 41.1%; P < 0.001), type 1 diabetes (11.3% vs. 2.8%; P < 0.001), ischemic heart disease (36.4% vs. 25.0%; P = 0.013), chronic renal failure (25.4% vs. 16.2%; P < 0.001), and an older age [74.6 ± 7.1 vs. 68.3 ± 7.2 (years); P < 0.001]. The OS group showed a greater prevalence of chronic ischemia of the lower extremities (22.8% vs. 9.4%; P < 0.001), a greater AAA diameter [61.2 ± 13.6 vs. 58.5 ± 13.8 (mm); P < 0.001], a greater aneurysm neck diameter [24.1 ± 3.9 vs. 23.3 ± 3.0 (mm); P = 0.002], and a shorter aneurysm neck length [15.1 ± 11.1 vs. 24.0 ± 11.1 (mm); P < 0.001]. Early mortality was low in both groups but higher with OS (1.9% vs. 0.3%; P = 0.046). OS [OR 16.98 (95% CI: 1.97-146.29) (P < 0.001)] and age [OR 1.22 (95% CI: 1.09-1.36) (P < 0.001)] were independent predictors of higher early mortality. However, there was no increase in mortality in the OS group in patients under 73.5 years (P = 0.996), and the differences increased over 73.5 years of age (P = 0.005). There were also more postoperative complications (23.9% vs. 9.7%; P < 0.001) and early reinterventions in the OS group (4.4% vs. 1.6%; P = 0.026). Only the prevalence of renal function impairment was greater in the EVAR group (6.6% vs. 3.5%; P = 0.034), but this complication resulted not significative in the multivariate analysis [OR 0.84 (95% CI: 0.41-1.69) (P = 0.618)]. The median duration of follow-up was 33 (range 0-175) and 59 months (range 0-190) for the EVAR and OS groups, respectively. The survival rate after 24 and 48 months was 92.9% and 83.9% (EVAR) versus 94.6% and 90.6% (OS) (P < 0.001). This difference was not significative in the multivariable analysis: hazard ratio (HR) 1.46 (95% CI 0.99 to 2.12); P = 0.060. OS also resulted in better freedom from reintervention rates for the same periods: 92.1% and 90.4% versus 92.9% and 88.1%, including multivariate analysis [HR 1.93 (95% CI 1.27 to 2.93) P = 0.002]. The factors independently associated to poorer survival were age [HR 1.09 (1.06-1.11); P < 0.001], chronic obstructive pulmonary disease [HR 1.39 (1.04-1.86); P = 0.026], and chronic renal failure [HR 2.08 (1.51-2.87); P < 0.001].
Conclusions: Elective AAA repair offers excellent middle-term outcomes with both OS and EVAR. EVAR reduces early mortality in the subgroup of patients older than 73.5 years. In patients younger than 73.5 years with a low to moderate surgical risk, EVAR offers no advantage over OS and therefore should not be regarded as the treatment of choice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.avsg.2018.12.089 | DOI Listing |
BJS Open
December 2024
Department of Molecular Medicine and Surgery, Stockholm Aortic Research Group, STAR, Karolinska Institutet, Stockholm, Sweden.
Background: The longitudinal effects of educational interventions in people with abdominal aortic aneurysm are largely unexplored. This prospective study investigated whether the anxiety-lowering effect of an eHealth intervention observed at the 1-month follow-up is maintained 1 year after abdominal aortic aneurysm surgery.
Methods: Those scheduled for surgical repair of abdominal aortic aneurysm were recruited in a single-centre randomized clinical trial.
J Vasc Surg Cases Innov Tech
April 2025
Division of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
This report details the case of an 84-year-old male with an infrarenal abdominal aortic aneurysm and a dilated right common iliac artery eligible for endovascular treatment. A bifurcated stent graft (Medtronic Endurant IIs) was used to treat the aneurysm. To address the concerns of instability of the right iliac limb, four endoanchors (Heli-FX EndoAnchor, Medtronic) were placed at the distal landing zone to provide additional fixation.
View Article and Find Full Text PDFHeliyon
January 2025
Department of Colorectal and Stomach Cancer Surgery-1, Jilin Cancer Hospital, Changchun, Jilin Province, China.
A 55-year-old woman with non-small cell lung carcinoma complained of epigastric pain, bloating, anorexia and postprandial nausea and vomiting over a five-year period. An upper gastrointestinal pan-glucosamine contrast examination revealed a distinctive large, hook-shaped, ptotic gastric lumen with normal motility. The contrast agent demonstrated an abnormal round-trip flow anterior to the spine at the duodenal level, with pooling and gradual passage through this region in strands after prolonged retention.
View Article and Find Full Text PDFCureus
December 2024
Infectious Diseases, Hospital Sultanah Aminah, Johor Bahru, MYS.
Mycotic aneurysms are rare but severe complications that can arise from systemic bacterial infections, including those caused by Salmonella species. These aneurysms can progress rapidly and are associated with high mortality. A 62-year-old man with poorly controlled type 2 diabetes mellitus presented to the hospital in septic shock.
View Article and Find Full Text PDFJVS Vasc Sci
December 2024
Department of Cardiovascular Science, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Treatment with an inhibitor of glucose use via glucose transporters (GLUT) has been shown to attenuate experimental abdominal aortic aneurysm (AAA) development in mice. Vascular smooth muscle cell (VSMC) signaling seems to be essential for angiotensin II (Ang II)-induced AAA in mice. Accordingly, we have tested a hypothesis that VSMC silencing of the major GLUT, GLUT1, prevents AAA development and rupture in mice treated with Ang II plus β-aminopropionitrile.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!